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Abstract
The radionuclide therapies for solid and liquid malignancies are emerging field nowadays. The targeted radionuclide 
therapies have been in use since 1945. In the past 20 years, due to advancement in the nanotechnology and targeting 
cell receptors; radionuclide therapies have emerged as a subspecialty in nuclear medicine. Through this article, we 
would like to briefly describe the evolution of peptide-based radionuclide therapies, with a little emphasis on their 
clinical applications.
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Introduction
So far, radiotherapy techniques have proved important in 
treating as well as prolonging the patients’ lives, depending 
on the type of cancer in the question. However, the success 
of these techniques is limited by their lack of specificity 
as the anticancer agents or cytotoxic technologies that 
do not distinguish between the cancerous regions and 
the normal tissues.[1] Radionuclide therapy acts the same 
way as the chemotherapy but targeting specific cells, by 
recognizing the presence or absence of specific receptors. 
Since the 1980s, treatment of neuroendocrine tumours 
has been treated using, I-131- Metaiodobenzylguanidine 
due to its high efficacy in treating chromaffin producing 
tumours (paraganglioma, pheochromocytoma and 
neuroblastoma).[2]
Clinical Importance of Peptide-based Radiopharma-
ceuticals on Cancer Therapy
Cancer therapy by the use of radionuclides involves the 
use of a variety of radionuclides labelled with monoclonal 
antibodies for specific tumours. At the basic level, this 
technique requires the monoclonal antibody to bind 
to the tumour-specific antigens to distinguish cancer 
cells from the normal cells and increase the therapeutic 
value of the radionuclides. After the first description of 
radio-immunotherapy by Korngold and Pressman in 1953, 
various radiopharmaceuticals have been developed by 
advanced techniques in genetic engineering and chelating 
methods.[3,4]
Somatisation and Somatostatin Receptors Biosyn-
thesis
The usual biosynthesis of somatostatin happens on 
several sites, including the nervous system (central 
and peripheral nervous system), gastrointestinal tract, 
kidney, retina, immune cells and placenta. However, 
the hypothalamus forms the principle biosynthetic site 
for somatostatin production. The process is activated by 
the high cytosolic calcium concentration and membrane 
depolarisation in neurons and peripheral secreting cells.[5] 
The biosynthesis happens in two stages, where the initial 
stage involves the production of somatostatin peptide by 
ribosomal mechanisms. This phase is followed by post-
translational cleavage of the peptide into smaller subsets, 
namely, somatostatin-14 and somatostatin-28, by the 
action of trypsin-like proteolytic enzymes. After synthesis, 
the release of SST is influenced by several chemicals, 
including nutrients, neurotransmitters, neuropeptides, 
cytokines, hormones and growth factors. Some of the 
examples of hormones that stimulate the release of 
somatostatin include the corticotrophin-release hormone, 
neurotensin and growth hormone-releasing hormone. On 
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the other hand, some of the substances that inhibit the 
release of somatostatin include leptin, cytokines, opiates 
and gamma-aminobutyric acid (GABA).[6]
Somatostatin Receptors
There are three classifications of somatostatin receptors, 
including the rhodopsin-like family, the GABA-like family 
and the glucagon-receptor-like family that belong to the 
G-protein coupled receptor family. A sound understanding 
of the structure and function of somatostatin receptors can 
be achieved by exploring the G-protein coupled receptors 
to which they belong. G-protein coupled receptors are 
composed of seven transmembrane alpha helices that 
are linked to each other by six loops with extracellular 
ligand-binding domains as well as an intracellular signal 
transduction domain.[7] They are activated by inhibition 
of adenylyl cyclase, causing a decrease in the intracellular 
levels of cAMP and calcium channels’ activity. Further 
subsequent events in this cascade include tyrosine 
phosphatases activation and the ultimate up-regulation 
of antimitosis. The initiation of this cascade also induces 
several other signal transduction pathways, including Src, 
Erk ½, MAP kinase, Na+ -H+ exchangers, protein kinase 
and p38 mitogen activation. In the end, all these pathways 
result in such changes as vascular contractility, ion/nutrient 
absorption, lowered intestinal motility, neurotransmission 
modulation, reduced cellular proliferation, and inhibition 
of exocrine/endocrine functions and among others.[8]
Subtypes of Somatostatin Receptors
At present, there are six known subtypes of somatostatin 
receptors, and they include ssr1, ssr2A, ssr2B, sstr3, sstr4 
and sstr5. These receptors have a fair distribution across 
all body organs including kidney, pancreas, nervous 
system and the gastrointestinal tract. All the six SSRS 
have a structural resemblance with G-protein coupled 
receptors, but they have functional differences due to 
such variations as carboxyl terminal and amino sequences. 
These differences result in the differential ligand affinities 
as well as specificities to ligands, in addition to the 
differential transmission of intracellular signals after 
activation. In human subjects, the six receptor subtypes 
are also present in the above-mentioned organs in addition 
to several others. For example, sstr1, sstr2B, sstr4, sstr5 
and sstr3 can also be found in the bronchial gland, sstr2B 
and sstr5 in the parotid gland and sstr1, sstr3 and sstr4 in 
the parathyroid gland.[9]
Somatostatin Analogues and Antitumour Effects
Both in vivo and ex vivo studies have demonstrated the 
antitumour activity of various somatostatin analogues. 
Studies on the consequences of octreotide on tumours 
conducted in the 1980s proved 20% partial response rate 
and 50% stable disease response rate.[10] In the 1990s, 
six studies on the effects of octreotide on advanced 
neuroendocrine tumours resulted in stable disease among 
15%–86% of the patients. Somatostatin analogues also 
provide relief of such as symptoms-like diarrhoea, 
wheezing and flushing, which is highly associated with 
neuroendocrine tumours. They two analogues act in 
a similar way as the natural somatostatin molecules 
in that after binding to somatostatin receptors; they 
initiate cascades of events that lead to direct or indirect 
anti-proliferative effect. Some of the effects of these 
analogues that are also present after the natural secretion 
of somatostatin include inhibition of cell signaling, protein 
synthesis, hormonal secretion and increased apoptosis as 
well as decreased cellular proliferation.[11]
Somatostatin-Receptor-positive Neuroendocrine 
Tumours
One of the common characteristics of neuroendocrine 
tumours is that they show overexpression of somatostatin 
receptors. Some of these tumours include gastrinoma, 
insulinoma, small cell lung cancer, glucagonoma, 
VIPoma and phaeochromocytoma. Around 80% of all 
of the above named neuroendocrine tumours exhibit 
the expression of somatostatin receptors on their 
cellular membranes making them important targets 
in somatostatin-based radiopharmaceuticals. The 
gastroenteropancreatic tumours are the most common 
in incidence. Under the WHO classification system 
based on histological features gastroenteropancreatic 
and neuroendocrine tumours is classified into four 
classes, namely mixed exocrine-endocrine carcinomas, 
poorly-differentiated neuroendocrine carcinomas, well-
differentiated neuroendocrine carcinomas and well-
differentiated neuroendocrine tumours.[12]
However, most of these tumours do not produce detectable 
hormones, and thus they remain undiagnosed until their 
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advanced stages of progression when such symptoms mass 
effects and metastases happen. Patients with non-metastatic 
well-differentiated neuroendocrine carcinomas have been 
observed to have a survival rate of 60–100% over 5 years, 
but those with distant metastasis have a survival rate of 29% 
over a similar period. Different neuroendocrine tumours 
produce varying amounts of each of the five subtypes of 
somatostatin receptors. On average, 68, 86, 46, 93 and 57% 
of all neuroendocrine tumours express sstr1, sstr2, sstr3, 
sstr4 and sstr5 on their cells, respectively, and this shows 
significant importance of somatostatin receptors on their 
diagnoses. VIPoma is the only tumour that expresses all 
the sstr from type 1–5 [Table 1].[13]
The Composition of Peptide-based Radiopharma-
ceuticals
Peptide-based radiopharmaceuticals comprise four 
parts that include a radionuclide, a targeting peptide, a 
bifunctional chelating agent and a linker moiety.
Targeting Peptides
A targeting peptide is a delivery vehicle that takes a 
radionuclide to a specific antigen expressed by tumours. 
Most targeting peptides are regulatory peptides that can 
be synthesised by solid-phase peptide synthesis. These 
peptides can also be modified further to incorporate 
prosthetic groups, spacer moieties and chelating agents. 
Furthermore, these peptides are also chemically stable 
meaning that they can undergo radiolabeling processes 
without recording significant changes. Their small sizes 
also allow for a rapid clearance to facilitate diffusion of 
radiopharmaceuticals to the tumour as well as its excretion 
to avoid residual effects. However, most of these peptides 
are subject to biodegradation by various peptidases present 
in different biological systems. As a result, bio-engineered 
monoclonal antibodies form the other preferred option.[14]
Bifunctional Chelating Agents
Bifunctional chelating agents provide a conjugation 
bridge between the targeting peptide and the radionuclide 
to prevent direct contact between the two components 
that would minimize the binding affinity of the 
biopharmaceutical for the targeted receptor. The choice 
of a bifunctional chelating agent depends on the oxidation 
state of the metallic radionuclide in the question, but in 
the end, it should allow for coupling with the peptide as 
well as a stable compound of the radiometal. Furthermore, 
the resultant radionuclide-chelate complex should be 
biologically inert to avoid competition of binding between 
the target receptor and the endogenous plasma proteins.[15]
Three chelating systems may be utilised by bifunctional 
chelating agents. One of them is the acyclic chelating 
system, which forms a complex between a radiometal 
and open-chain polyaminopolycarboxylates under mild 
conditions for temperature-sensitive biomolecules 
and fast metal-binding kinetics for short-lived 
radiometals. Two of the most common example of 
acyclic chelators for radiopharmaceutical applications 
include diethylenetriamine pentaacetic acid (DTPA) and 
ethylenediamine tetraacetic acid.[16]
Another chelating system utilised by the bifunctional 
chelating agent is the macroacyclic system. The product 
of the macroacyclic chelating systems is kinetically more 
inert and thermodynamically more stable than acyclic 
chelating systems. Some of the common macroacyclic 
chelating agents include triaza, cyclen-type and cyclam-
type tetraaza chelators. For example, DOTA (cyclen-
type 1,4,7,10,-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid), which is ubiquitous for +3-charged radionuclides.[16]
Bioconjugation
The conjugation of bifunctional chelating agents with a 
peptide can also be achieved by conjugating to a peptide 
sequence through the side chain functionalities of the 
amino acids or the primary N-terminal amine. Some of 
the conjugation strategies use to produce bioconjugation, 
in this case, include utilising azides, maleimides, 
N-hydroxysuccinimide esters and isothiocyanates. Of all 
these examples, the N-hydroxysuccinimide esters are the 
most commonly used especially after their activation to 
form a primary amine of the amine or lysine group at the 
peptide sequence’s N-terminus.[17]
Linkers
A linker is a radiopharmaceutical component that has 
two orthogonal sites of conjugation for connection 
between the targeting peptide and the radionuclide-chelate 
compound. It serves as a spacer between the radionuclide 
and the targeting peptide to prevent binding interference 
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between the radionuclide and the targeting peptide and 
sustains a high binding affinity for the targeted receptor 
and the peptide. If the linker is electrically charged, 
hydrophilic or lipophilic, it modifies the pharmacokinetics 
of the conjugate to influence its clearance from the body, 
excretion or uptake by the tumours. In addition, a linker 
provides an avenue for the creation of a bifunctional 
radioconjugate by providing additional functionality. One 
of the commonly used linkers is beta-alanine.[17]
Clinically Available Radiopharmaceuticals Yttrium-90 
(Y-90)
Yttrium-90 is a short-lived beta-emitting radionuclide that 
can be milked and purified from its parent radioisotope and 
strontium-90. Its β-particles have the maximum energy of 
2.27 MeV and tissue penetration of 12 mm. with half-life 
of 64 h. At present Y-90, a radioactive isotope used in 
drugs for the treatment of various cancers, including 
lymphoma, leukaemia, ovarian, colorectal, pancreatic 
and bone cancers.[18]
Lutetium 177 (Lu-177)
Lu-177 produced through three approaches, namely, 
charged particle acceleration and neutron irradiation in 
a nuclear reactor and a cyclotron. The radioactive decay 
of Lu-177 results in the emission of two primary radio 
particles, namely, gamma radiation (γ-photon) and beta-
particles. Of the beta particles emitted during radioactive 
decay of Lu-177, 498 keV accounts for 79.3% and 
380 keV accounts for 9.1% while 176 keV accounts for 
12.2% of all beta-emissions by abundance.[19]
Gallium-68
The physical half-life of gallium-68 is 67.71 min, 
and it makes it compatible with the pharmacokinetics 
characteristics of such low molecular weight 
radiopharmaceuticals as peptides, antibody fragments, 
oligonucleotides and aptamers. 89% of gallium-68 
decay happens through positron emission, while the 
rest 11% happens by electron capture. On average, the 
mean positron energy emitted by gallium-68 in every 
disintegration is 740 KeV. 68Ge/68Ga generator is 
almost an ideal generator strategy due to the long half-life 
(270.95 days) of Ge-68 (parent radionuclide) and the 
short half-life (67.71 min) of the resultant radionuclide 
(Ga-68) (Roesch and Riss, 2010). The Ga-69(p,2n) 
Ge-68 reaction in proton accelerator is the preferred 
production route of Ge-68, and it requires the use of 
ion exchange chromatography as a perfect separation 
system that prevents the break-through between the parent 
radionuclide and the soluble daughter.[20]
Radiolabelled Somatostatin Analogues
Octreotide, lanreotide and vaprotide
Octreotide has a long cyclic structure, and its chemical 
properties are similar to those of somatostatin making 
it a somatostatin agonist. Octreotide has been clinically 
tried in tumour treatments where it has been shown to 
over resolutions for such conditions as thyrotrophinomas 
and carcinoid syndrome. One of the radionuclides 
conjugated to octreotide to produce a radiolabelled 
somatostatin analogue for radionuclide targeted therapies 
is indium-111. This conjugation provides 111In-DTPA 0, 
octreotide, which emits Auger electrons and gamma-
rays after administration in patients with metastatic 
tumours. Lanreotide is a somatostatin analogue with 
similar properties as octreotide as well as long-acting 
pharmacological properties. Lanreotide can be treated with 
indium-111 and yttrium-90 to produce two radiolabelled 
somatostatin analogues, namely, 111In-DOTA-lanreotide 
and 90Y-DOTA-lanreotide, respectively. 111In-DOTA-
lanreotide derives its tumour therapeutic effects from 
the natural antitumour effects of lanreotide as well as 
the emission of Auger electrons and gamma-rays from 
Table 1: Percentage of cells that express SSTR in GI neuroendorine tumours[13]
Tumour type Percentage of cell that express sstr 
sstr 1 sstr 2 sstr 3 sstr 4 sstr 5 
Insulinoma 33 100 33 100 67 
Gastrinoma 33 50 17 83 50 
Glucagonoma 67 100 67 67 67 
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after radioactive decay of indium-111. On the other 
hand, 90Y-DOTA-lanreotide acts in the same way, but its 
yttrium-90 emits beta particles.[21]
Radiolabelled somatostatin analogues and radio 
imaging
Since neuroendocrine tumours express more somatostatin 
receptors than the normal tissue, somatostatin analogues 
have been seen as important molecules in for localizing 
the tumour by the radio imaging protocol. Among all 
the five major subtypes of somatostatin receptors, sstr2 
is the most overexpressed receptor in neuroendocrine 
tumours. Somatostatin imaging is mainly applied for 
four major reasons, including the determination of the 
sstr status about disease treatment, accurately stage the 
disease, follow-up on the disease and restage the disease. 
Octreotide was the first somatostatin analogue to be used 
in single photon emission tomography somatostatin 
receptor analogue imaging in the late 1980s.[22] Octreotide 
exhibits a high affinity for sstr5 and sstr2, but a lesser 
affinity for sstr3 is making it a modern fit for imaging 
neuroendocrine tumours. Due to this affinity for sstr2 and 
sstr5, a radiolabelled octreotide complex with indium-111 
was developed. This complex has 68-h long half-life 
and when used for imaging an allowance of 24-48 h is 
necessary to ensure hepatobiliary and renal clearance to 
reduce the background activity.[23]
Conclusion
On the new horizon of personalised medicine, radioactive 
material can be coupled with tumour-specific targeting 
agents such that imaging biomarkers of the disease 
can be combined with radionuclide therapy. The other 
members of health-care team need to be educated about the 
benefits and risks for such procedures. We need to adopt 
a practical approach for manufacturing and delivering 
radiopharmaceuticals, assessing patient eligibility, 
ensuring post-therapy follow-up and addressing cost 
issues, which will be essential for success. The question 
that is likely to arise now is not, can we do it but rather, 
where does it fit into our treatment strategy and how do 
we best implement it?
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